Micropaque Scanner (Barium Sulfate)

• Micropaque Scanner, containing barium sulfate, is employed in radiographic procedures that require enhanced visualization of the gastrointestinal tract.
• Gastrointestinal tract imaging: delineates the stomach, small intestine and colon during X‑ray studies, improving diagnostic accuracy.
• Upper gastrointestinal series: enhances visualization of the esophagus, stomach and duodenum for assessment of structural abnormalities.
• Barium swallow study: provides contrast for the pharynx and esophagus to evaluate dysphagia and motility disorders.

• Barium sulfate consists of high‑atomic‑number barium particles that are insoluble in water. When administered orally, the suspension coats the mucosal surface of the gastrointestinal lumen. The dense barium atoms strongly attenuate X‑ray photons, creating a radiopaque outline that appears white on radiographic images. Because the compound is not absorbed, it remains confined to the GI tract and is eliminated unchanged in the feces.

Oral barium sulfate may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Nausea: mild queasiness after ingestion.
• Abdominal cramping: temporary discomfort in the stomach.
• Constipation: slowed bowel movements lasting a few days.
• Taste alteration: metallic or chalky sensation in the mouth.

Serious or Rare Side Effects

• Allergic reaction: rash, itching, swelling that may require medical attention.
• Severe abdominal pain: intense pain indicating possible obstruction.
• Aspiration pneumonia: inhalation of barium into the lungs leading to respiratory distress.

Prior to using Micropaque Scanner, several precautionary measures should be considered to ensure patient safety.

• Patient assessment: evaluate for known hypersensitivity to barium sulfate or prior adverse reactions.
• Gastrointestinal obstruction risk: avoid use in patients with suspected bowel perforation or severe constipation.
• Hydration: encourage adequate fluid intake before and after the procedure to facilitate passage of the contrast.
• Medication timing: separate administration of barium from oral drugs that may have reduced absorption.
• Pregnancy considerations: consider alternative imaging modalities when feasible, as safety data are limited.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Barium sulfate can affect the absorption of certain orally administered medicines, leading to clinically relevant interactions.

Major Interactions (Avoid)

• Tetracycline antibiotics: barium binds and markedly reduces absorption; concurrent use should be avoided.
• Fluoroquinolone antibiotics: decreased bioavailability when taken with barium; avoid simultaneous administration.
• Levothyroxine: barium may impair thyroid hormone absorption; avoid co‑administration.

Moderate Interactions (Monitor Closely)

• Iron supplements: may form complexes with barium, reducing effectiveness of both; schedule doses several hours apart.
• Calcium-containing antacids: can alter contrast quality and drug absorption; monitor patient response.
• Other oral medications (e.g., bisphosphonates): potential reduced uptake; advise timing adjustments and monitor therapeutic levels.